Table 1.
Patient characteristics (N = 43)
| Characteristics | Patients (%) |
|---|---|
| Age (years) | |
| Median (range) | 67 (40–82) |
| Sex (%) | |
| Male | 24 (55.8) |
| Female | 19 (44.2) |
| ECOG PS (%) | |
| 0 | 16 (37.2) |
| 1 | 22 (51.2) |
| 2 | 5 (11.6) |
| Primary site (%) | |
| Head | 22 (51.2) |
| Body and tail | 21 (48.8) |
| Stage (%) | |
| III | 10 (23.3) |
| IV | 33 (76.7) |
| Chemotherapy regimen | |
| Gemcitabine | 24 (55.8) |
| TS-1 | 7 (16.2) |
| Gemcitabine plus TS-1 | 12 (28.0) |
| Previous CA19-9 (U/mL) | |
| Median (range) | 761 (1–28,487) |
| Previous CEA (ng/ml) | |
| Median (range) | 7.8 (1.6–311) |
ECOGPS = Eastern Cooperative Oncology Group performance status, CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen